Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy or radiation therapy and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy with topotecan, cyclophosphamide, cisplatin, and vincristine plus radiation therapy and peripheral stem cell transplantation in treating children with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Collaborator: National Cancer Institute (NCI)
• Treatments: Amifostine; Cisplatin; Cyclophosphamide; Lenograstim; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven medulloblastoma or supratentorial primitive neuroectodermal tumor

• Average-risk group:

• Localized tumor with no overt evidence of invasion beyond the posterior fossa

• Less than 1.5 cm2 residual tumor/imaging abnormality

• No CNS or extraneural metastasis (confirmed by bone scan)

• Brain stem invasion allowed if above criteria met

• High-risk group:

• Metastatic disease within the neuraxis (subarachnoid dissemination) OR greater than 1.5 cm^2 residual disease at the primary site after surgery

• No bone involvement by bone scan

• Must begin study within 28 days of definitive surgery

PATIENT CHARACTERISTICS:

Age

• 3 to 20 at diagnosis

Performance status

• ECOG 0-3 (except patients with posterior fossa syndrome)

Life expectancy

• Not specified

Hematopoietic

• WBC greater than 3,000/mm^3

• Absolute neutrophil count greater than 1,500/mm^3

• Platelet count greater than 100,000/mm^3

• Hemoglobin greater than 10 g/dL

Hepatic

• Bilirubin less than 1.5 mg/dL

• SGPT less than 1.5 times normal

Renal

• Creatinine less than 1.2 mg/dL OR

• Creatinine clearance greater than 70 mL/min

Other

• Not pregnant or nursing

• Negative pregnancy test

• HIV negative

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No prior chemotherapy

Endocrine therapy

• Prior corticosteroids allowed

Radiotherapy

• No prior radiotherapy

Surgery

• See Disease Characteristics